Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
NC Tebbutt, MM Parry, D Zannino, AH Strickland, GA Van Hazel, N Pavlakis, V Ganju, D Mellor, A Dobrovic, VJ Gebski
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2013
This study was supported with an unrestricted educational grant by Merck Serono. Drugs were provided by Merck Serono and Sanofi-Aventis. Numerous individuals from many institutions participated to complete this study. We thank everyone involved for their efforts.